ScholarLens Back to search
1999•Zhonghua chuanranbing zazhiRequires access

A comparative trial of thymosin α1 vs. thymosin α1 combined with interferon α1b in the treatment of chronic hepatitis B

Xianghui Wu

Open publisher page 0 citations

Abstract

Objective To observe the efficacy and safety of Tα1 vs. Tα1 combined with IFN α in the treatment of chronic hepatitis B. Methods Thirty eight patients with chronic hepatitis B were randomly divided into group A and B. Patients in both groups received Tα1 for six months. However, patients in group A received IFN α coincidently for six months. Results At the end of treatment, ALT level decreased in the patients of both group A and group B( P =0.0043 and P =0.0036, respectively), which decreased 96.6±38.3IU/L( P =0.00189) in group A and 81.93±56.39IU/L in group B respectively. HBV DNA level decreased 130±283 mEq/ml( P =0.0019) in group A and 373±825 mEq/ml in group B( P =0.019).Conclusion The Tα1 or Tα1 combined with IFN α is efficient to treat patients with chronic hepatitis B.

About this research paper

What this paper is about

Objective To observe the efficacy and safety of Tα1 vs. Tα1 combined with IFN α in the treatment of chronic hepatitis B. Methods Thirty eight patients with chronic hepatitis B were randomly divided into group A and B. Patients in both groups received Tα1 for six months. However, patients in group A received IFN α coincidently for six months. Results At the end of treatment, ALT level decreased in the patients of both group A and group B( P =0.0043 and P =0.0036, respectively), which decreased 96.6±38.3IU/L( P =0.00189) in group A and 81.93±56.39IU/L in group B respectively. HBV DNA level decreased 130±283 mEq/ml( P =0.0019) in group A and 373±825 mEq/ml in group B( P =0.019).Conclusion The Tα1 or Tα1 combined with IFN α is efficient to treat patients with chronic hepatitis B.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To observe the efficacy and safety of Tα1 vs. Tα1 combined with IFN α in the treatment of chronic hepatitis B. Methods Thirty eight patients with chronic hepatitis B were randomly divided into group A and B. Patients in both groups received Tα1 for six months. However, patients in group A received IFN α coincidently for six months. Results At the end of treatment, ALT level decreased in the patients of both group A and group B( P =0.0043 and P =0.0036, respectively), which decreased 96.6±38.3IU/L( P =0.00189) in group A and 81.93±56.39IU/L in group B respectively. HBV DNA level decreased 130±283 mEq/ml( P =0.0019) in group A and 373±825 mEq/ml in group B( P =0.019).Conclusion The Tα1 or Tα1 combined with IFN α is efficient to treat patients with chronic hepatitis B.

Key concepts: Chronic hepatitis, Medicine, Gastroenterology, Internal medicine, Thymosin, Group B, Group A, Hepatitis B

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
A comparative trial of thymosin α1 vs. thymosin α1 combined with interferon α1b in the treatment of chronic hepatitis B — Research Paper | ScholarLens